Every pharmacy deals with inventory shrinkage to some degree — counting errors, breakage, expired product write-offs. Most of it is routine and doesn’t trigger any regulatory obligation. Controlled substances are different: a discrepancy that would just be a shrug for over-the-counter inventory can be a reportable event when it involves scheduled drugs. Knowing where that line sits matters, because failing to report a significant loss is itself a compliance problem separate from the loss itself.
Ordinary shrinkage vs reportable loss
Shrinkage is a normal part of retail and pharmacy operations — small discrepancies between what inventory records show and what’s physically on the shelf, arising from counting errors, breakage, spoilage, or minor administrative mistakes. For non-controlled inventory, this is generally just an operational and financial issue, addressed through internal inventory controls.
For controlled substances, DEA regulations distinguish between routine discrepancies (small counting variances that a reasonable internal review can explain) and a “significant loss” — an amount and pattern that isn’t reasonably explained by normal handling and record-keeping variance. Only the latter category triggers a federal reporting obligation. There’s no universal numeric threshold DEA applies uniformly across all pharmacies; what counts as “significant” is evaluated in context, considering factors like the type of controlled substance, the quantity involved relative to normal handling volume, and whether the loss appears to reflect theft or diversion versus recordkeeping error.
What counts as a “significant loss”
Federal regulations require registrants to report to DEA, in writing, any theft or significant loss of controlled substances upon discovery. Loss types that commonly trigger reporting include:
- Suspected employee theft or diversion
- Robbery or burglary involving controlled substances
- Loss in transit (from a wholesaler or between pharmacy locations)
- Unexplained inventory discrepancies that internal investigation can’t account for through recordkeeping or counting error
A single missed count that’s resolved after a recount typically isn’t reportable. A pattern of unexplained shortages for a specific drug over multiple inventory cycles, or a large one-time discrepancy with no plausible administrative explanation, is much more likely to cross into reportable territory.
The reporting process
When a loss is determined to be significant, the standard federal reporting mechanism is DEA Form 106 (“Report of Theft or Loss of Controlled Substances”), filed electronically upon discovery of the loss. The form asks for details including the substances and quantities involved, how the loss was discovered, and whether local law enforcement was notified.
State requirements typically layer on top of the federal obligation. Many states require separate notification to the state board of pharmacy or state controlled substance authority, sometimes on a different timeline or form than DEA’s, and some require notification to local law enforcement as a matter of state law rather than DEA regulation. Because Form 106 reports theft or loss and doesn’t substitute for a state board notification where one is required, a pharmacy may need to make two separate reports for a single incident. For a deeper look at the specific federal form and process, see our guide on controlled substance theft/loss reporting and Form 106.
Internal investigation before reporting
Before concluding a loss is reportable, most pharmacies run an internal investigation to rule out administrative explanations: recounting physical inventory, reviewing dispensing records against purchase records, checking for data entry errors in the pharmacy system, and reviewing any relevant surveillance footage. This isn’t about avoiding a report that should be made — it’s about accurately characterizing what happened before filing, since the report itself asks for specifics about how the loss was discovered and what’s believed to have caused it.
Good ongoing inventory practices reduce both the frequency of shrinkage and the time needed to investigate when it happens: perpetual inventory tracking for Schedule II drugs, regular cycle counts rather than relying solely on the biennial inventory, and documented chain-of-custody for controlled substance handling between staff. Our guide on controlled substance inventory requirements covers the baseline recordkeeping obligations that make loss investigation possible in the first place, and our piece on controlled substance destruction requirements covers the related process for properly disposing of expired or unusable controlled substance stock, since destruction records are sometimes confused with loss reports during an audit.
Consequences of underreporting
Failing to report a significant loss is a compliance failure independent of the loss itself, and it’s the kind of gap that shows up during a DEA inspection or state board audit even years later, since inventory and purchase records typically remain available for review well beyond the incident date. A pattern of unreported or under-investigated discrepancies can also be a factor state boards weigh in disciplinary proceedings, separate from any DEA enforcement action.
What qualifies as a “significant loss,” specific reporting timelines, and state notification requirements vary and are subject to change, so confirm current thresholds and procedures with DEA guidance, your state board of pharmacy, and qualified counsel when a loss situation arises.
Keep controlled substance compliance requirements organized by state
RxByState tracks controlled substance recordkeeping, reporting, and inventory requirements across all 50 states, helping pharmacies stay current as state-specific rules evolve. Start your free trial →